Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
VitaSpring Biomedical Reports No Revenue and Increased Losses for Six Months Ending July 31, 2026
VitaSpring Biomedical Reports No Revenue and Net Loss Reduction for Fiscal Year Ending January 31, 2026
VitaSpring Biomedical Reports Net Loss of $75,844 with No Revenue for Q2 2026
VitaSpring Biomedical Reports No Revenue, Increased Operating Expenses, and Ongoing Financial Challenges
VitaSpring Biomedical Reports No Revenue, Significant Loss Reduction in Latest Financial Results
VitaSpring Biomedical Reports $80,541 Net Loss with No Revenue for Quarter Ending April 30, 2025
VitaSpring Biomedical Reports No Revenue and Decreased Net Loss for Fiscal Year Ending January 31, 2025
VitaSpring Biomedical Reports No Revenue and Increased Losses for Three and Nine Months Ending October 31, 2024
VitaSpring Biomedical Reports Continued Revenue Absence and Net Loss for Six Months Ending July 31, 2024
VitaSpring Biomedical Reports $216,831 Net Loss, Maintains Revenue at Zero
VitaSpring Biomedical Reports No Revenue and $1.1 Million Net Loss for Fiscal Year Ending January 31, 2024
VitaSpring Biomedical Reports No Revenue and Significant Losses in Latest Financial Filing
VitaSpring Biomedical Reports No Revenue and Increased Losses in Latest Quarter
VitaSpring Biomedical Reports No Revenue and Significant Losses for Fiscal Year Ending January 31, 2023